Background
==========

Colorectal cancer (CRC) ranks third among the most frequent malignancies in the Western world, and despite significantly improved treatment modalities, CRC remains a major cause of cancer mortality \[[@b1-medscimonit-21-2595],[@b2-medscimonit-21-2595]\]. At an estimated 608 000 deaths worldwide each year, CRC is the fourth most common cause of deaths among all cancers, accounting for 8% of all cancer-related deaths \[[@b3-medscimonit-21-2595]\]. Nearly 150 000 are newly diagnosed with CRC annually in the US and approximately one-third of CRC patients die from this disease \[[@b4-medscimonit-21-2595]\]. CRC is characterized by late clinical presentation and a relatively rapid disease progression, which is the primary underlying reason for increased mortality and morbidity in patients with this malignancy \[[@b3-medscimonit-21-2595],[@b5-medscimonit-21-2595]\]. However, advances in treatment modalities, including surgery, radiation therapy, and chemotherapy, have steadily improved the 5-year survival rate for CRC \[[@b6-medscimonit-21-2595]\]. Etiologically, interactions of genetic and environmental factors play central roles in the pathogenesis of CRC \[[@b7-medscimonit-21-2595]\]. The exact processes underlying pathogenesis of CRC are complex and only partially understood, but current research suggests body fat and its associated metabolic dysregulation play a central role \[[@b8-medscimonit-21-2595]\]. A growing body of evidence suggests that adiponectin (*ADIPOQ*) may be the link between obesity and CRC \[[@b9-medscimonit-21-2595],[@b10-medscimonit-21-2595]\].

*ADIPOQ* is an adipocyte-derived peptide hormone and insulin-sensitizing adipokine expressed as a single subunit and is abundantly secreted by adipocytes into circulation \[[@b11-medscimonit-21-2595]\]. *ADIPOQ* and its receptors (ADIPOR1/2) are expressed in colonic tissues as well, and the expression of ADIPOR1 and ADIPOR2 is found at higher levels in colorectal carcinomas, compared to normal colonic epithelium \[[@b12-medscimonit-21-2595]\]. *ADIPOQ* appears to exert its influence in preneoplastic colonic lesions to modulate cell growth through activating, altering, or interacting with some pathways including leptin and NF-kB pathway \[[@b13-medscimonit-21-2595]\]. In human, *ADIPOQ* is encoded by the *ADIPOQ* gene located on chromosome 3q27 and is comprised of three exons with 2 introns \[[@b14-medscimonit-21-2595]\]. In human plasma, the circulating *ADIPOQ* level ranges between 3 to 30 μg/ml \[[@b15-medscimonit-21-2595]\] and is reduced in patients with insulin resistance, type II diabetes \[[@b16-medscimonit-21-2595]\], obesity \[[@b17-medscimonit-21-2595]\], cardiovascular disease \[[@b18-medscimonit-21-2595]\], gastric cancer \[[@b19-medscimonit-21-2595]\] and colorectal adenomas and carcinoma \[[@b20-medscimonit-21-2595]\]. Low plasma *ADIPOQ* levels in these disease states are accompanied by reduced *ADIPOQ* gene expression in adipose tissue caused by single nucleotide polymorphisms (SNPs) in *ADIPOQ* gene \[[@b20-medscimonit-21-2595],[@b21-medscimonit-21-2595]\]. Although the function of most of these SNPs remains unclear, three common SNPs, rs1501299 (276G/T), rs2241766 (45T/G) and rs266729 (−11377C/G), are suspected to play a direct role in the susceptibility to some diseases, including coronary heart disease, type 2 diabetes mellitus, squamous cell esophageal cancer and liver disease \[[@b22-medscimonit-21-2595]--[@b25-medscimonit-21-2595]\]. Consistent with this notion, previous studies linked these polymorphisms with altered serum levels of *ADIPOQ* \[[@b26-medscimonit-21-2595]\], obesity \[[@b27-medscimonit-21-2595]\], and CRC \[[@b28-medscimonit-21-2595],[@b29-medscimonit-21-2595]\]. However, other studies failed to confirm such associations with these diseases, and the results remain controversial \[[@b30-medscimonit-21-2595],[@b31-medscimonit-21-2595]\]. Considering the conflict results existed, we conducted this meta-analysis with the hypothesis that the *ADIPOQ* rs2241766 T\>G, rs1501299 G\>T and rs266729 C\>G SNPs may correlate with an increased the risk of CRC.

Material and Methods
====================

Search strategy
---------------

A literature research was conducted using PubMed, Cochrane Library, Ovid, Embase, Wanfang and China National Knowledge Infrastructure (CNKI) databases, to identify studies published prior to October 2014. Relevant studies were identified using the terms: "adiponectin or *ADIPOQ*" and "polymorphisms or variant" and "colorectal tumor or cancer". The search was confined to humans. A manual search of references of the original articles related with this topic was used to identify additional studies. If the data or data subsets were published in more than one paper, only the paper with the largest sample size was enrolled.

Study selection
---------------

Studies were selected for meta-analysis if they met the inclusion criteria as follows: (1) case-control study design; (2) studies that investigated the association between the *ADIPOQ* SNPs and CRC; (3) study subjects were CRC patients confirmed by histopathology in case group; (4) the enrolled studies provided *loci* information of *ADIPOQ* rs2241766 T\>G, rs1501299 G\>T and rs266729 C\>G. The exclusion criteria were: (1) reviews and summaries; (2) repetitive publications; (3) no raw data of the *ADIPOQ* genotype.

Data extraction
---------------

Two investigators extracted data independently and reached agreements on all the items. If there were any disagreements between the 2 investigators, the data were re-examined and, following a thorough discussion and evaluation of each item, a consensus was reached. Data extracted from the enrolled papers included first author, publication year, country, ethnicity, number of cases, age, genotyping method and SNP of *loci* information. The methodological quality of enrolled studies was assessed by critical appraisal skill program (CASP) criteria by 2 of the independent investigators independently (<http://www.casp-uk.net/>). The following criteria were used to rate each item: the study addressed a clearly focused issue (CASP01); the research problem is appropriate and the research design answers the research problem (CASP02); the cases were recruited in an acceptable way (CASP03); the controls were selected in an acceptable way (CASP04); the measurement for exposure factors is accurate to minimize bias (CASP05); the study controls other important confounding factors (CASP06); the research result is complete (CASP07); the research result is precise (CASP08); the research result is reliable (CASP09); the research result is applicable to the local population (CASP10); the research result fits with other available evidence (CASP11).

Statistical methods
-------------------

Pooled odds risk (OR) and 95% confidence intervals (CI) were calculated with the usage of fixed-effects or random-effects model. Z test was employed to detect the significance of overall effect size \[[@b32-medscimonit-21-2595]\], and forest plots were conducted to display values of OR at 95%CI between case and control groups. Heterogeneity of the combined studies was assessed with Cochran's Q-statistic test and *I*^2^ test \[[@b33-medscimonit-21-2595],[@b34-medscimonit-21-2595]\]. The P value of Cochran's Q-statistic of below 0.05 was considered statistically significant heterogeneity. The *I*^2^ test provides a measure of the degree of heterogeneity in the results. Typically, values of 0\~25% are considered to represent no heterogeneity, 25\~50% to be modest heterogeneity, 50\~75% to be large heterogeneity, and 75\~100% to be extreme heterogeneity. A random-effects model was applied if there was heterogeneity (P\<0.05 or *I*^2^\>50%); otherwise, a fixed-effects model was employed \[[@b35-medscimonit-21-2595]\]. Univariate and multivariate meta-regression analyses were used to estimate the source of heterogeneity, and Monte Carlo simulation (MCS) was performed to correct and verify the results \[[@b33-medscimonit-21-2595],[@b36-medscimonit-21-2595],[@b37-medscimonit-21-2595]\]. Sensitivity analysis was conducted by omitting individual studies sequentially to assess stability of the results. The Egger's test, funnel plots, and classic fail-safe N were used to identify publication bias \[[@b38-medscimonit-21-2595]--[@b40-medscimonit-21-2595]\].

Results
=======

Study characteristics
---------------------

The database search strategy retrieved 188 potentially relevant studies. Based on the inclusion criteria, after excluded 20 duplicates, 17 animal studies, 54 studies unrelated to the research topics, and 8 letters, reviews, or meta-analyses, 8 cohort studies, 14 studies not relevant to *ADIPOQ*, 22 studies not relevant to *ADIPOQ* polymorphism, 34 studies unrelated to CRC, and 5 studies that had no enough information, a sum of 6 studies, published between 2008 and 2014, were included in this meta-analysis \[[@b28-medscimonit-21-2595],[@b41-medscimonit-21-2595]--[@b45-medscimonit-21-2595]\]. The 6 selected studies contained a total of 1897 CRC (Asians: 1190; White: 707) patients and 2475 healthy controls (Asians: 1325; white: 1150). Of the 6 studies, 3 studies were performed in Asians, in China; the other 3 studies were performed in whites, with 2 studies in the US and 1 trial in Mexico. The sample sizes of the studies varied between 58 and 441. The uniform genotyping method in the studies was polymerase chain reaction with the restriction fragment length polymorphism (PCR-RFLP). In the controls, the distribution of genotypes was in accordance with Hardy-Weinberg equilibrium (HWE) for the all selected trials except for 1 study \[[@b42-medscimonit-21-2595]\] for rs1501299 G\>T, 1 study for rs266729 C\>G \[[@b45-medscimonit-21-2595]\], and 1 study \[[@b41-medscimonit-21-2595]\] for rs1501299 G\>T and rs2241766 T\>G. Baseline characteristics and quality scores of all included studies are displayed in [Table 1](#t1-medscimonit-21-2595){ref-type="table"} and [Figure 1](#f1-medscimonit-21-2595){ref-type="fig"}.

Association between *ADIPOQ* rs2241766 T\>G and susceptibility to CRC
---------------------------------------------------------------------

Five studies investigated the correlation between SNP of *ADIPOQ* rs2241766 T\>G and the susceptibility to CRC. Heterogeneity test revealed that no heterogeneity existed under allele and dominant models, and thus a fixed-effect model was used (P\>0.05). The results of this meta-analysis suggested that rs2241766 T\>G SNP was associated with an increased risk of CRC (allele model: OR=1.147, 95% CI=1.033\~1.272, P=0.010 ([Figure 2A](#f2-medscimonit-21-2595){ref-type="fig"}); dominant model: OR=1.229, 95% CI=1.077\~1.401, P=0.002) ([Figure 2B](#f2-medscimonit-21-2595){ref-type="fig"}). Subgroup analysis based on ethnicity indicated that the rs2241766 T\>G SNP increased the risk of CRC in Asian population (allele model: OR=1.198, 95% CI=1.062\~1.353, P=0.003; dominant model: OR=1.282, 95% CI=1.095\~1.500, P=0.002), while no significant association between rs2241766 T\>G and CRC was found in whites (allele mode: OR=1.015, 95% CI=0.829\~1.241, P=0.888; dominant model: OR=1.115, 95% CI=0.879\~1.416, P=0.370) ([Table 2](#t2-medscimonit-21-2595){ref-type="table"}).

Association between *ADIPOQ* rs1501299 G\>T and susceptibility to CRC
---------------------------------------------------------------------

Six studies investigated the correlation between SNP of *ADIPOQ* rs1501299 G\>T and the susceptibility to CRC. Heterogeneity test revealed that no heterogeneity existed under allele and dominant models; therefore, a fixed-effects model was used (P\>0.05). The results of this meta-analysis suggested rs1501299 G\>T under allele model had no significant association with the susceptibility to CRC (OR=0.936, 95% CI=0.852\~1.027, P=0.163) ([Figure 3A](#f3-medscimonit-21-2595){ref-type="fig"}), while rs1501299 G\>T under dominant model increased the risk of CRC (OR=0.874, 95% CI=0.766\~0.998, P=0.047) ([Figure 3B](#f3-medscimonit-21-2595){ref-type="fig"}). Subgroup analysis by ethnicity indicated that the rs1501299 G\>T SNP was associated with increased risk of CRC in Asians (allele model: OR=0.833, 95% CI=0.738\~0.940, P=0.003; dominant model: OR=0.790, 95% CI=0.675\~0.925, P=0.003), while no significant association was found in whites (allele mode: OR=1.111, 95% CI=0.960 \~1.287, P=0.159; dominant model: OR=1.118, 95% CI=0.875\~1.428, P=0.374) ([Table 2](#t2-medscimonit-21-2595){ref-type="table"}).

Association between *ADIPOQ* rs266729 C\>G and susceptibility to CRC
--------------------------------------------------------------------

Three studies investigated the correlation between SNP of *ADIPOQ* rs266729 C\>G and the susceptibility to CRC. Heterogeneity test revealed that there was heterogeneity under allele model, and thus a random-effects model was used (P\<0.05). However, no heterogeneity was detected under the dominant model, and thus a fixed-effects model was applied (P\>0.05). The results of this meta-analysis suggested rs266729 C\>G SNP under allele model was associated with increases risk of CRC (OR=0.850, 95% CI=0.754\~0.960, P=0.009) ([Figure 4A](#f4-medscimonit-21-2595){ref-type="fig"}), while no significant association was detected under the dominant model (OR=0.963, 95% CI=0.816\~1.136, P=0.656) ([Figure 4B](#f4-medscimonit-21-2595){ref-type="fig"}). Subgroup analysis by ethnicity suggested that in Asians, rs266729 C\>G SNP under allele model increased the risk of CRC (OR=0.839, 95% CI=0.720\~0.979, P=0.026), while no significant correlation with CRC was found under the dominant model (OR=1.091, 95% CI=0.871\~1.367, P=0.449). There was also no strong association between rs266729 C\>G SNP and the risk of CRC in whites (allele model: OR=0.868, 95% CI=0.714\~1.056, P=0.157; dominant model: OR=0.833, 95% CI=0.653\~1.062, P=0.140) ([Table 2](#t2-medscimonit-21-2595){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

Univariate analysis suggested that publication year ([Figure 5A](#f5-medscimonit-21-2595){ref-type="fig"}), country ([Figure 5B](#f5-medscimonit-21-2595){ref-type="fig"}), ethnicity ([Figure 5C](#f5-medscimonit-21-2595){ref-type="fig"}), SNP ([Figure 5D](#f5-medscimonit-21-2595){ref-type="fig"}), language ([Figure 5E](#f5-medscimonit-21-2595){ref-type="fig"}) and sample size ([Figure 5F](#f5-medscimonit-21-2595){ref-type="fig"}) were all not the main source of heterogeneity or key factors influencing the overall effect size (P\>0.05). Multivariate analysis further verified the result of univariate analysis ([Table 3](#t3-medscimonit-21-2595){ref-type="table"}). The results of sensitivity analyses for rs2241766 T\>G (allele: [Figure 6A](#f6-medscimonit-21-2595){ref-type="fig"}; dominant: [Figure 6B](#f6-medscimonit-21-2595){ref-type="fig"}), rs1501299 G\>T (allele: [Figure 7A](#f7-medscimonit-21-2595){ref-type="fig"}; dominant: [Figure 7B](#f7-medscimonit-21-2595){ref-type="fig"}) and rs266729 C\>G (allele: [Figure 8A](#f8-medscimonit-21-2595){ref-type="fig"}; dominant: [Figure 8B](#f8-medscimonit-21-2595){ref-type="fig"}) suggested that no single study had a marked effect on the pooled ORs. The funnel plots of the differences in gene frequencies of rs2241766 T\>G, rs1501299 G\>T and rs266729 C\>G were symmetrical, suggesting no publication bias. Classic fail-safe N and Egger test further verified that no publication bias existed ([Figure 9](#f9-medscimonit-21-2595){ref-type="fig"}).

Discussion
==========

Globally, CRC is known as one of the most frequent gastrointestinal tumors \[[@b46-medscimonit-21-2595]\]. Over the past decade, the correlations between *ADIPOQ* SNPs and the risk of cancers, including CRC, have been extensively investigated, with conflicting results \[[@b47-medscimonit-21-2595]\]. We conducted the present meta-analysis to explore the correlations between *ADIPOQ* rs2241766 T\>G, rs1501299 G\>T, and rs266729 C\>G SNPs and the susceptibility to CRC. We found that rs2241766 T\>G SNP, rs1501299 G\>T under dominant model, and rs266729 C\>G SNP under allele model were strongly correlated with an increased susceptibility to CRC, indicating that the *ADIPOQ* polymorphisms confer a marked risk of CRC. *ADIPOQ* is a 30-kDa adipocytokine hormone secreted by the adipose tissues, which mediates antineoplastic as well as anti-angiogenic effects through binding its receptors, Adipo-R1 and Adipo-R2, which are also expressed in colorectal cancer tissues \[[@b11-medscimonit-21-2595]\]. *ADIPOQ* is insulin-sensitizing, anti-inflammatory, anti-atherogenic, and anti-angiogenic \[[@b48-medscimonit-21-2595],[@b49-medscimonit-21-2595]\]. *In vitro*, *ADIPOQ* directly controls the malignant behavior of tumor cells, including cell proliferation, adhesion, invasion, and colony formation \[[@b50-medscimonit-21-2595]\]. *ADIPOQ* influences angiogenesis through inducing apoptosis of endothelial cells, thus functioning as an angiogenesis inhibitor \[[@b51-medscimonit-21-2595],[@b52-medscimonit-21-2595]\]. The SNPs reduce the expression and function of *ADIPOQ*, and thus influence CRC susceptibility. Consistent with this, several epidemiology studies showed that low *ADIPOQ* levels are correlated with increased susceptibility to multiple obesity-associated malignancies, including breast, endometrial, prostate, and colorectal cancers in both cross-sectional and prospective studies \[[@b53-medscimonit-21-2595],[@b54-medscimonit-21-2595]\]. Suggested mechanisms by which *ADIPOQ* might play a part in the CRC development include suppressing inflammation, improving insulin sensitivity, inhibiting cell growth and inducing apoptosis \[[@b30-medscimonit-21-2595]\]. However, contrary to our results, Mingyang Song et al. reported findings that did not support any correlation between the known *ADIPOQ* SNPs and CRC \[[@b30-medscimonit-21-2595]\]. This null result might be due to the fact that the plasma *ADIPOQ* data in that study was only from a subset of the 2 cohorts of the consortium, which precluded a simultaneous analysis of the genetic component and the circulating *ADIPOQ* levels in relation to CRC in the same set of subjects.

Subgroup analysis based on ethnicity indicated that the rs2241766 T\>G, rs1501299 G\>T and under allele model rs266729 C\>G increased the risk of CRC in Asians, while no significant association between *ADIPOQ* SNPs and risk of CRC was observed in whites. We suspect genetic polymorphisms at other *loci* such as in protein disulfide isomerase (PDI) or in the other members of the multi-subunit *ADIPOQ* complex, geographical position, dietary habits, lifestyle or limitations in existing detection methods could account for these observations, and we plan to follow up with further studies to address ethnic differences about the association between *ADIPOQ* SNPs and the risk of CRC.

Some limitations in the present meta-analysis should be pointed out. First, due to the publication limitations or incomplete data, several relevant studies were not able to be enrolled in this analysis. Second, the number of enrolled trials, especially for rs266729 C\>G SNP was not large enough for a comprehensive analysis, and some trials with small size, such as the study by Partida-Perez M et al., might not have sufficiently statistical power to obtain the real correlation. Third, our results were based on unadjusted estimates, and insufficient information for data analysis might cause confounding bias. Despite these limitations, our analysis also had some advantages. First, substantial number of cases and controls were pooled from different trials, which significantly increased statistical power of the meta-analysis. Second, the quality of case-control studies included in current meta-analysis was relatively satisfactory and met our predefined inclusion criteria. Third, we did not find any publication bias, suggesting that the overall pooled result is unbiased.

Conclusions
===========

In summary, the rs2241766 T\>G SNP, under dominant model rs1501299 G\>T and under allele model rs266729 C\>G SNP was associated with an increase the risk of CRC, suggesting that the rs2241766 T\>G SNP, rs1501299 G\>T, and rs266729 C\>G SNPs might be correlated with the increased susceptibility to CRC and may be useful biomarkers for early diagnosis of CRC.
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###### 

Baseline characteristics of the studies included in this meta-analysis.

  First author                                       Year   Country   Disease   Sample   Total   Sample size   Gender (M/F)   Age (years)   Genotyping methods   Gene           SNP                                  
  -------------------------------------------------- ------ --------- --------- -------- ------- ------------- -------------- ------------- -------------------- -------------- -------------- ---------- ---------- -----------
  Liu WH-a \[[@b42-medscimonit-21-2595]\]            2014   China     CRC       Blood    800     400           400            233/167       --                   22\~75         55.74          PCR-RFLP   *ADIPOQ*   rs2241766
  Liu WH-b \[[@b42-medscimonit-21-2595]\]            2014   China     CRC       Blood    800     400           400            233/167       --                   22\~75         55.74          PCR-RFLP   *ADIPOQ*   rs1501299
  Zhang Y-b \[[@b45-medscimonit-21-2595]\]           2012   China     CRC       Blood    740     370           370            245/125       226/144              63.13 ±12.47   61.97 ±10.37   PCR-RFLP   *ADIPOQ*   rs1501299
  Zhang Y-a \[[@b45-medscimonit-21-2595]\]           2012   China     CRC       Blood    740     370           370            245/125       226/144              63.13 ±12.47   61.97 ±10.37   PCR-RFLP   *ADIPOQ*   rs2241766
  Zhang Y-c \[[@b45-medscimonit-21-2595]\]           2012   China     CRC       Blood    740     370           370            245/125       226/144              63.13 ±12.47   61.97 ±10.37   PCR-RFLP   *ADIPOQ*   rs266729
  He B-c \[[@b28-medscimonit-21-2595]\]              2011   China     CRC       Blood    975     420           555            280/140       339/216              62.88 ±12.32   61.71 ±10.65   PCR-RFLP   *ADIPOQ*   rs266729
  He B-b \[[@b28-medscimonit-21-2595]\]              2011   China     CRC       Blood    975     420           555            280/140       339/216              62.88 ±12.32   61.71 ±10.65   PCR-RFLP   *ADIPOQ*   rs1501299
  He B-a \[[@b28-medscimonit-21-2595]\]              2011   China     CRC       Blood    975     420           555            280/140       339/216              62.88 ±12.32   61.71 ±10.65   PCR-RFLP   *ADIPOQ*   rs2241766
  Partida-Perez M-b \[[@b43-medscimonit-21-2595]\]   2010   Mexico    CRC       Blood    170     68            102            36/32         78/24                58             --             PCR-RFLP   *ADIPOQ*   rs1501299
  Partida-Perez M-a \[[@b43-medscimonit-21-2595]\]   2010   Mexico    CRC       Blood    170     68            102            36/32         78/24                58             --             PCR-RFLP   *ADIPOQ*   rs2241766
  Tsilidis KK \[[@b44-medscimonit-21-2595]\]         2009   USA       CRC       Blood    589     208           381            96/112        173/208              62.8 ±11.4     62.8 ±11.5     PCR-RFLP   *ADIPOQ*   rs1501299
  Kaklamani VG-b \[[@b41-medscimonit-21-2595]\]      2008   USA       CRC       Blood    1099    441           658            --            --                   255/186        211/447        PCR-RFLP   *ADIPOQ*   rs1501299
  Kaklamani VG-a \[[@b41-medscimonit-21-2595]\]      2008   USA       CRC       Blood    1099    441           658            --            --                   255/186        211/447        PCR-RFLP   *ADIPOQ*   rs2241766
  Kaklamani VG-c \[[@b41-medscimonit-21-2595]\]      2008   USA       CRC       Blood    1099    441           658            --            --                   255/186        211/447        PCR-RFLP   *ADIPOQ*   rs266729

M -- male; F -- female; CRC -- colorectal cancer; PCR-RFLP -- polymerase chain reaction-restriction fragment length polymorphism; *ADIPOQ* -- adiponectin; SNP -- single nucleotide polymorphisms; a -- rs2241766; b -- rs1501299; c -- rs266729.

###### 

Comparisons of genotype and allele frequencies between the case and the control groups.

  SNP                                                rs2241766 T\>G   rs1501299 G\>T   rs266729 C\>G                                                                       
  ---------------------------------------- --------- ---------------- ---------------- --------------- -------------- -------------- ------- -------------- -------------- -------
  M allele *vs.* W allele (allele model)   Asians    1.198            1.062\~1.353     0.003           0.833          0.738\~0.940   0.003   0.839          0.720\~0.979   0.026
  Caucasians                               1.015     0.829\~1.241     0.888            1.111           0.960\~1.287   0.159          0.868   0.714\~1.056   0.157          
  Overall                                  1.147     1.033\~1.272     0.01             0.936           0.852\~1.027   0.163          0.85    0.754\~0.960   0.009          
  WM + MM *vs.* WW (dominant model)        Asians    0.833            0.738\~0.940     0.003           0.79           0.675\~0.925   0.003   1.091          0.871\~1.367   0.449
  Caucasians                               1.111     0.960\~1.287     0.159            1.118           0.875\~1.428   0.374          0.833   0.653\~1.062   0.14           
  Overall                                  1.229     1.077\~1.401     0.002            0.874           0.766\~0.998   0.047          0.963   0.816\~1.136   0.656          
  MM *vs.* WW (homozygous model)           Overall   1.17             0.896\~1.528     0.248           0.858          0.690\~1.069   0.172   1.037          0.756\~1.423   0.821
  MM *vs.* WM (heterozygous model)         Overall   1.07             0.817\~1.402     0.623           0.946          0.788\~1.136   0.554   0.934          0.681\~1.281   0.672
  MM *vs.* WW + WM (recessive model)       Overall   1.061            0.819\~1.375     0.653           1.001          0.841\~1.190   0.995   1.049          0.774\~1.421   0.758

SNP -- single nucleotide polymorphisms; OR -- odds risk; 95% CI -- 95% confidential intervals.

###### 

Meta-regression analyses of potential source of heterogeneity.

  Heterogeneity factors   Coefficient   SE        t       *P* (Adjusted)   95% CI     
  ----------------------- ------------- --------- ------- ---------------- ---------- ---------
  Year                    0.008         0.048     0.16    1.000            −0.107     0.122
  Country                 0.361         0.279     1.29    0.608            −0.299     1.022
  Ethnicity               −0.687        0.545     −1.26   0.625            −1.977     0.603
  Language                0.111         0.123     0.90    0.832            −0.180     0.402
  SNP                     −0.073        0.043     −1.72   0.381            −0.174     0.027
  Sample                  −0.001        \<0.001   −1.20   0.660            \<−0.001   \<0.001

SE -- standard error; LL -- lower limit; UL -- upper limit; 95%CI -- 95% confidence intervals; SNP -- single nucleotide polymorphism.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
